title: Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Mena
authors.forename: Pilar
authors.initials: P
authors.lastname: Vázquez
authors.forename: Ángeles
authors.initials: Á
authors.lastname: Castro
authors.forename: Soledad
authors.initials: S
authors.lastname: López
authors.forename: Laura
authors.initials: L
authors.lastname: Bello
authors.forename: José D
authors.initials: JD
authors.lastname: Pedreira
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D019380:Anti-HIV Agents / Q000008:administration & dosage; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000008:administration & dosage*; D000068898:Raltegravir Potassium; D012293:Rifampin / Q000008:administration & dosage*; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D012293:Rifampin